From MAIA's closing valuation on Tuesday, this $10.27 target suggests an upside potential of over 700%!
Critical Report Info:
Valuation - Building on the strengthened balance sheet and improved funding visibility, we have revisited our underlying assumptions for THIO in NSCLC. We increase our probability of success (PoS) from 25% to 35%, reflecting the program’s advancement into a pivotal Phase 3 trial, supportive efficacy signals observed in earlier studies, and regulatory momentum, including Fast Track designation. In our view, the transition into a registrational study represents the achievement of a key clinical milestone and enhances visibility into the development pathway.
...
Based on these revised assumptions, alongside our updated comparable company analysis, we derive an illustrative valuation of $10.27 per share, contingent on successful execution by the company.
#2. Another Major Analyst Target Suggest Serious Upside Potential (Quadruple-Digit!).
Noble Capital Markets - $14.00 Target - (Potential upside of 1,000+% from Tuesday's close.)
Key Report Details:
Conclusion. Patients in the trial had advanced disease with relapsed NSCLC. We see these data as additional evidence of a sustainable response from combination treatment with ateganosine and cemiplimab. These data are consistent with prior findings showing improvements in overall survival, progression-free survival, and median survival in patients with ICI-resistant and chemo-resistant NSCLC. We are reiterating our Outperform rating and $14 price target.
#3. MAIA Biotechnology Activates First U.S. Site For Ongoing International Phase 2 Expansion Trial Of Novel Telomere Targeting Treatment Targeting Advanced Non-Small Cell Lung Cancer.
MAIA Biotechnology’s activation of its first U.S. site for the Phase 2 THIO-101 expansion trial marks a major growth milestone, significantly increasing access to a large underserved population of advanced non-small cell lung cancer patients.
With approximately 50,000 patient resistant cases annually in the U.S., the expansion enhances enrollment potential while building on strong efficacy data already exceeding standard-of-care benchmarks in disease control, response rates, and survival.
Combined with ongoing global sites, MAIA is strengthening its clinical footprint and advancing ateganosine toward broader validation and future commercialization in oncology markets worldwide.
#4. MAIA Biotechnology Expects Recent $33Mn Capital Raise To Fully Fund Ongoing Pivotal Phase 3 Trial Of Novel Telomere-Targeting Anticancer Therapy.
MAIA Biotechnology’s successful $33Mn capital raise provides full funding visibility for its pivotal Phase 3 trial, reinforcing investor confidence in its late-stage telomere-targeting therapy, ateganosine.
Strong participation signals belief in both clinical momentum and commercial potential, while FDA Fast Track designation further validates the therapy’s importance in treating third-line non-small cell lung cancer.
Statistical analyses indicate a high probability of Phase 3 success, and upcoming interim data could support early regulatory discussions, positioning MAIA for accelerated approval and meaningful market entry.
#5. MAIA Biotechnology Reports Overall Survival Exceeding Two Years For Eight Patients In Ongoing Phase 2 Clinical Trial In Non-Small Cell Lung Cancer.
MAIA Biotechnology reported compelling Phase 2 data showing overall survival exceeding two years in multiple heavily pretreated non-small cell lung cancer patients, far surpassing historical benchmarks.
These results, presented at a major international oncology conference, strengthen the case for ateganosine as a transformative immunotherapy targeting telomeres while activating immune responses.
With a $50Bn market opp., MAIA is well positioned for future growth and validation ahead. -----
MAIA Biotechnology, Inc. (NYSE American: MAIA) tops Wednesday's watchlist.
Keep a lookout for updates heading your way shortly. Talk soon.
All the best, Dane James Editor Market Pulse Today
(Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.)
*MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, MPT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.
Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired for a period beginning on 04/29/2026 and ending on 04/29/2026 to publicly disseminate information about (MAIA:US) via digital communications. Under this agreement, TD Media LLC has paid Thousand Sun Media LLC seven thousand five hundred USD ("Funds"). To date, including under the previously described agreement, Thousand Sun Media LLC has been paid ninety one thousand five hundred USD ("Funds"). These Funds were part of the ninety two thousand five hundred USD funds that TD Media LLC received from a third party named Sica Media LLC who did not receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.
Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (MAIA:US).
Please see important disclosure information here: https://marketpulsetoday.com/disclosure/maia-obgqw/#details |
0 التعليقات:
إرسال تعليق